Home Newsfeeds Barclays Maintains Overweight on Axalta Coating Sys, Raises Price Target to $30

Barclays Maintains Overweight on Axalta Coating Sys, Raises Price Target to $30

Barclays analyst Michael Leithead maintains Axalta Coating Sys (NYSE:AXTA) with a Overweight and raises the price target from $28 to $30.

byBenzinga Newsdesk

January 5, 2023

1 minute read

Barclays analyst Michael Leithead maintains Axalta Coating Sys (NYSE:AXTA) with a Overweight and raises the price target from $28 to $30.

Ultragenyx Announces Update To Conference Call Timing To Discuss New Data From GTX-102 In Patients With Angelman Syndrome; Conference Call Now Scheduled For Monday, April 15 At 8:00 a.m. ET

By Benzinga Newsdesk

April 12, 4:23 PM

Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link belowNOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that

RARE

Analyst Ratings

UBS Maintains Neutral Rating for EQT: Here’s What You Need To Know

By Benzinga Insights

August 31, 1:00 PM

UBS has decided to maintain its Neutral rating of EQT (NYSE:EQT) and lower its price target from $51.00…

EQT

BlackSky Wins Air Force Research Contract To Track Vehicles In Real Time From Space

By Benzinga Newsdesk

October 16, 8:50 AM

Automated target recognition service will fuse multiple satellite data sources, maintain vehicle custody and disseminate intelligence worldwideBlackSky Technology Inc. (NYSE:BKSY) won a competitive U.S. Air Force

BKSY

US Forms Team To Help Countries Defend Against China’s Economic ‘Coercion’ – Bloomberg

By Shivani Kumaresan

April 29, 7:53 AM

Discover how nations are seeking the 'Lithuania treatment' amid rising economic coercion from China. Learn how Washington's intervention empowers countries facing trade pressures, prompting proactive strategies for economic resilience.

SPY

Barclays Maintains Overweight on Axalta Coating Sys, Raises Price Target to $30

Related Posts

Ultragenyx Announces Update To Conference Call Timing To Discuss New Data From GTX-102 In Patients With Angelman Syndrome; Conference Call Now Scheduled For Monday, April 15 At 8:00 a.m. ET

UBS Maintains Neutral Rating for EQT: Here’s What You Need To Know

BlackSky Wins Air Force Research Contract To Track Vehicles In Real Time From Space

US Forms Team To Help Countries Defend Against China’s Economic ‘Coercion’ – Bloomberg